Evidence map›Paper›PMID 31882677›Full record

ArticleScientific reports2019

Characterization of a five-microRNA signature as a prognostic biomarker for esophageal squamous cell carcinoma.

Jun Yu, Ming Zhu, Min Lv, Xiaoliu Wu, Xiaomei Zhang, Yuanying Zhang, Jintian Li, Qin Zhang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Learning-based Cancer Treatment Outcome Prognosis using Multimodal Biomarkers.IEEE transactions on radiation and plasma medical sciences · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jun YuDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Ming ZhuDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Min LvDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Xiaoliu WuDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Xiaomei ZhangDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Yuanying ZhangDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Jintian LiDepartment of Molecular Biology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China.
Qin ZhangDepartment of Thoracic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, NO. 42 Baizi Ting, Xuanwu Distinct, Nanjing, 210009, China. 13901591757@163.com.
Nanjing Medical University · CNJiangsu Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to identify a miRNAs signature for predicting overall survival (OS) in esophageal squamous cell carcinoma (ESCC) patients. MiRNA expression profiles and corresponding clinical information of 119 ESCC patients were obtained from NCBI GEO and used as the training set. Differentially expressed miRNAs (DEmiRNAs) were screened between early-stage and late-stage samples. Cox regression analysis, recursive feature elimination (RFE)-support vector machine (SVM) algorithm, and LASSO Cox regression model were used to identify prognostic miRNAs and consequently build a prognostic scoring model. Moreover, promising target genes of these prognostic miRNAs were predicted followed by construction of miRNA-target gene networks. Functional relevance of predicted target genes of these prognostic miRNAs in ESCC was analyzed by performing function enrichment analyses. There were 46 DEmiRNAs between early-stage and late-stage samples in the training set. A risk score model based on five miRNAs was built. The five-miRNA risk score could classify the training set into a high-risk group and a low-risk group with significantly different OS time. Risk stratification ability of the five-miRNA risk score was successfully validated on an independent set from the Cancer Genome Atlas (TCGA). Various biological processes and pathways were identified to be related to these miRNAs, such as Wnt signaling pathway, inflammatory mediator regulation of TRP channels pathway, and estrogen signaling pathway. The present study suggests a pathological stage-related five-miRNA signature that may have clinical implications in predicting prognosis of ESCC patients.

Indexed as

Gene Expression Regulation, NeoplasticAgedAlgorithmsBiomarkers, TumorCarcinoma, Squamous CellEsophageal NeoplasmsFemaleGene Expression ProfilingGene Regulatory NetworksHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorMicroRNAs

Identifiers

PMID31882677
PMCPMC6934627
OpenAlexW2997890804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.